{
"ranked_hypotheses": [
{
"rank": 1,
"title": "Altered PSAP Cleavage Generates Pro-inflammatory Fragments in Oligodendrocytes",
"mechanism": "Disease-associated proteases (cathepsins/MMPs) alter PSAP processing in oligodendrocytes, producing pathogenic saposin fragments that over-activate GPR37-IL-6 signaling and drive neuroinflammation.",
"target_gene": "PSAP",
"confidence_score": 0.7,
"novelty_score": 0.7,
"feasibility_score": 0.5,
"impact_score": 0.8,
"composite_score": 0.69,
"testable_prediction": "Inhibit cathepsin D activity in oligodendrocyte-specific PSAP-overexpressing PD mouse models and measure reduced IL-6 levels and preserved dopaminergic neurons.",
"skeptic_concern": "GPR37 is ubiquitously expressed, yet the mechanism is claimed oligodendrocyte-unique; need to explain why altered PSAP cleavage selectively affects oligodendrocyte signaling."
},
{
"rank": 2,
"title": "Oligodendrocyte-Specific GPR37 Signaling Amplification via IL-6 Autocrine Loop",
"mechanism": "Oligodendrocytes exhibit enhanced GPR37-IL-6 positive feedback signaling compared to other cell types, creating a cell-intrinsic amplification loop that sustains neuroinflammation.",
"target_gene": "GPR37",
"confidence_score": 0.55,
"novelty_score": 0.6,
"feasibility_score": 0.5,
"impact_score": 0.75,
"composite_score": 0.61,
"testable_prediction": "Single-cell RNA-seq comparing GPR37 and IL-6 co-expression in oligodendrocytes vs microglia from PD vs control brains to demonstrate cell-type specific amplification.",
"skeptic_concern": "Requires demonstrating that oligodendrocyte GPR37 signaling is mechanistically distinct from microglial GPR37 signaling despite shared receptor expression."
},
{
"rank": 3,
"title": "Microglial-Oligodendrocyte Cross-Talk Exacerbates PSAP-GPR37-IL-6 Axis",
"mechanism": "Microglial activation initially triggers PSAP release from oligodendrocytes, which then drives secondary oligodendrocyte-intrinsic neuroinflammation via GPR37-IL-6, making oligodendrocytes amplifiers rather than initiators.",
"target_gene": "IL6",
"confidence_score": 0.5,
"novelty_score": 0.55,
"feasibility_score": 0.4,
"impact_score": 0.7,
"composite_score": 0.54,
"testable_prediction": "Conditional IL-6 knockout in oligodendrocytes crossed with MPTP PD model to determine if neuroprotection requires blocking oligodendrocyte-derived vs microglial-derived IL-6.",
"skeptic_concern": "This model partially reverts to microglia as initiators, contradicting the paper's central claim that oligodendrocytes are the primary drivers."
}
],
"consensus_points": [
"The PSAP-GPR37-IL-6 axis is a legitimate signaling pathway with relevance to PD neuroinflammation",
"Oligodendrocytes contribute meaningfully to inflammatory environments in PD, even if initiating vs amplifying roles remain debated",
"Targeting this axis therapeutically is a promising but underexplored strategy requiring cell-type specificity"
],
"dissent_points": [
"SKEPTIC challenges whether oligodendrocyte-specific effects are mechanistically distinct given ubiquitous PSAP and GPR37 expression; THEORIST and EXPERT maintain that the functional outcome (neurotoxicity) justifies the claim regardless of expression breadth"
],
"debate_summary": "Theorists propose that altered PSAP cleavage generates pathogenic fragments driving the PSAP-GPR37-IL-6 axis specifically in oligodendrocytes, representing a novel therapeutic target; skeptics question the cell-type specificity given ubiquitous expression of pathway components, suggesting either unique oligodendrocyte signaling amplification or microglial priming must be invoked to explain the claimed hierarchy. Expert consensus favors H1 as most druggable but acknowledges that resolving the cell-type specificity paradox is essential before translation."
}